Download PDF
Thromb Haemost 1969; 21(02): 320-324
DOI: 10.1055/s-0038-1653541
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

Intoxication with Phenprocoumon (Marcoumar) Pharmacokinetics and Side Effects

K Seiler
1   Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the University Department of Medicine (Head: Prof .Dr. F .Koller), Bürgerspital, Basel, Switzerland
,
F Duckert
1   Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the University Department of Medicine (Head: Prof .Dr. F .Koller), Bürgerspital, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
10 June 2018 (online)

    Permissions and Reprints

Summary

A case of severe Marcoumar intoxication is described. Eleven hours after the intake a plasma concentration of 15.75 µg/ml was found which corresponds approximately to the 5-fold therapeutic concentration. Repeated administration of vitamin K1 made it possible to avoid extreme lowering of the activity of the clotting factors II, VII and X and to prevent bleeding. Side effects were not observed. The biologic half-life of Phenprocoumon has been found to be shortened at high plasma concentration (3.7 instead of 5.9 days). It is probable that in extreme concentration the drug is less strongly bound to the plasma proteins.

 

  • References

  • 1 Aggeler P. M, O’Reilly R. A. The pharmacological basis of oral anticoagulant therapy. In: Pathogenesis and Treatment of thromboembolic Diseases. International Symposium Basle. Ed. Koller F, Duckert F, Streuli F. 227 F. K. Schattauer; Stuttgart: 1965
    Google Scholar
  • 2 Baumgartner H. R, Gronquist M, Wobmann P, Streuli F, Duckert F. Die Messung der Thrombocytenadhäsivität. Schweiz, med. Wschr 97 Nr. 50, 1674 1967;
    PubMedGoogle Scholar
  • 3 Douglas A. S. Anticoagulant therapy. 159 Blackwell Scientific Publications; Oxford: 1962
    Google Scholar
  • 4 Duckert F. Mécanisme de la Coagulation. Röntgen und Laboratoriumspraxis 13 L 224 1960;
    PubMedGoogle Scholar
  • 5 Hellem A. J. The adhesiveness of human blood platelets in vitro. Thesis. Scand. J. clin. Lab. Invest 12 Suppl. 51 1960;
    PubMedGoogle Scholar
  • 6 Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar 3-(Phenyl- propyl)-4-oxycumarin und seinen Antagonisten Konakion (synthetisches Vitamin KJ. Schweiz, med. Wschr 83: 20 471 1953;
    PubMedGoogle Scholar
  • 7 Shapiro S. Complications of Treatment. In: Clinical Anticoagulant Therapy. Ed. Myron V. i. gran. 275 Lea and Febinger; Philadelphia: 1965
    Google Scholar
  • 8 Seiler K, Duckert F. Properties of 3-(l-phenyl-propyl)-4-oxycoumarin (Marcoumar®) in the plasma when tested in normal cases and under the influence of drugs. Thrombos. Diathes. haemorrh. (Stuttg) 19: 389 1968;
    PubMedGoogle Scholar
  • 9 Zuckschwerdt L, Thies H. A. Nebenwirkungen von Antikoagulantien und Fibrinolytika. VII. Hamburger Symposium über Blutgerinnung. F. K. Schattauer; Stuttgart: 1965
    Google Scholar